| 8.64 0.09 (1.05%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.18 |
1-year : | 11.89 |
| Resists | First : | 8.72 |
Second : | 10.18 |
| Pivot price | 7.65 |
|||
| Supports | First : | 7.51 |
Second : | 6.76 |
| MAs | MA(5) : | 8.09 |
MA(20) : | 7.61 |
| MA(100) : | 8.16 |
MA(250) : | 8.24  |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 89.2 |
D(3) : | 71.9 |
| RSI | RSI(14): 59.6 |
|||
| 52-week | High : | 14.43 | Low : | 2.68 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ REPL ] has closed below upper band by 3.6%. Bollinger Bands are 22.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 8.73 - 8.77 | 8.77 - 8.8 |
| Low: | 8.24 - 8.27 | 8.27 - 8.31 |
| Close: | 8.58 - 8.64 | 8.64 - 8.71 |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Sat, 21 Feb 2026
Replimune Group, Inc. (REPL) Stock Analysis: Unpacking a 50% Potential Upside in Biotechnology - DirectorsTalk Interviews
Fri, 20 Feb 2026
Replimune Stock: Multiple Shots On Goal But A High Risk Binary Approaches (NASDAQ:REPL) - Seeking Alpha
Thu, 12 Feb 2026
Wall Street Analysts Predict a 65.72% Upside in Replimune Group (REPL): Here's What You Should Know - Yahoo Finance
Sun, 08 Feb 2026
Is Replimune Group (NASDAQ:REPL) A Risky Investment? - simplywall.st
Thu, 05 Feb 2026
Johnson Fistel, PLLP Begins Investigation on Behalf of - GlobeNewswire
Tue, 03 Feb 2026
Replimune burns cash as April 10 RP1 FDA action date approaches - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 78 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 106.5 (%) |
| Shares Short | 14,400 (K) |
| Shares Short P.Month | 14,760 (K) |
| EPS | -3.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.35 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.9 % |
| Return on Equity (ttm) | -96.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -263 (M) |
| Levered Free Cash Flow | -161 (M) |
| PE Ratio | -2.49 |
| PEG Ratio | 0 |
| Price to Book value | 2.57 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|